Immunofoco Presents Preclinical Data for In Vivo CAR T Candidate IMV102 at AACR 2026

Immunofoco announced in a press release the presentation of preclinical data for its in vivo BCMA targeting CAR T candidate IMV102 at the American Association for Cancer Research Annual Meeting 2026. The results showed that IMV102 achieved strong and durable anti tumor activity in multiple myeloma models.

IMV102 was developed using Immunofoco’s iMAGIC platform, which uses a lentiviral vector system with a mutated MxV glycoprotein and a T cell targeting module to enable selective targeting and transduction of T cells in vivo. In laboratory studies, IMV102 demonstrated efficient gene delivery in T cell lines with minimal activity in non target cells such as hepatocytes and Kupffer cells.

In animal models, IMV102 generated CAR T cells that produced significant tumor inhibition and maintained stable body weight with no major safety issues. The therapy showed controlled CAR T cell expansion and balanced immune activity as indicated by plasma IFN gamma levels.

Immunofoco stated that the company plans to advance IMV102 into clinical development and expand the use of its iMAGIC platform across oncology and autoimmune disease programs.